Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,305 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Regulatory
286 approval records across 2 jurisdictions, including tumor-agnostic approvals.
| Drug | Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|---|
| Zanubrutinib | US FDA | Waldenstrom Macroglobulinemia | This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Waldenström's macroglobulinemia (WM).accelerated | approved | Jun 10, 2025 | openfda |
| Zanubrutinib | US FDA | Mantle Cell Lymphoma | Mantle cell lymphoma (MCL) who have received at least one prior therapy. | approved | Jun 10, 2025 | openfda |
| Zanubrutinib | US FDA | Follicular Lymphoma | Relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy. | approved | Jun 10, 2025 | openfda |
| Zanubrutinib | US FDA | Waldenstrom Macroglobulinemia | This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Waldenström's macroglobulinemia (WM).accelerated | approved | Jun 10, 2025 | openfda |
| Zanubrutinib | US FDA | Marginal Zone Lymphoma | Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti–CD20-based regimen. | approved | Jun 10, 2025 | openfda |
| Zanubrutinib | US FDA | Mantle Cell Lymphoma | Mantle cell lymphoma (MCL) who have received at least one prior therapy. | approved | Jun 10, 2025 | openfda |
| Zanubrutinib | US FDA | Follicular Lymphoma | Relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy. | approved | Jun 10, 2025 | openfda |
| Zanubrutinib | US FDA | Waldenstrom Macroglobulinemia | This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Waldenström's macroglobulinemia (WM).accelerated | approved | Nov 14, 2019 | openfda |
| Zanubrutinib | US FDA | Marginal Zone Lymphoma | Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti–CD20-based regimen. | approved | Nov 14, 2019 | openfda |
| Zanubrutinib | US FDA | Follicular Lymphoma | Relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy. | approved | Nov 14, 2019 | openfda |
| Zanubrutinib | US FDA | Mantle Cell Lymphoma | Mantle cell lymphoma (MCL) who have received at least one prior therapy. | approved | Nov 14, 2019 | openfda |
| Ziftomenib | US FDA | Acute Myeloid Leukemia | KOMZIFTI is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 ( NPM1 ) mutation who have no satisfactory alternative treatment options [see Dosage and Administration ( 2.1 ), Clinical Pharmacology ( 12.1 ), and Clinical Studies ( 14 )] . KOMZIFTI is a menin inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 ( NPM1 ) mutation who have no satisfactory alternative treatment options. ( 1 ) | approved | Nov 13, 2025 | openfda |
Data updated 20 hours agoSource updated unknown
Curated evidence
Counts of CIViC evidence items mentioning each therapy for this entity or its descendants. Presence here is not an approval.
| Therapy | Evidence items (count) | Sensitivity / response | Resistance |
|---|---|---|---|
| Dasatinib | 254 | 133 | 121 |
| Imatinib | 114 | 48 | 66 |
| Bosutinib | 89 | 30 | 59 |
| Imatinib Mesylate | 86 | 8 | 78 |
| Axitinib | 54 | 16 | 38 |
| Nilotinib | 50 | 17 | 33 |
| Sorafenib | 44 | 27 | 17 |
| Sunitinib | 39 | 36 | 3 |
| Venetoclax | 37 | 4 | 33 |
| Midostaurin | 33 | 28 | 4 |
| Ponatinib | 32 | 26 | 6 |
| Mercaptopurine | 31 | 2 | 28 |
| Doxorubicin |
Regulatory status is jurisdiction-specific and changes over time. This page is not treatment guidance.
| 29 |
| 1 |
| 28 |
| Thioguanine | 29 | 0 | 28 |
| Melphalan | 24 | 0 | 24 |
| Quizartinib | 21 | 13 | 7 |
| Gilteritinib | 20 | 17 | 3 |
| Crizotinib | 17 | 12 | 5 |
| Cytarabine | 17 | 5 | 12 |
| Daunorubicin | 15 | 4 | 11 |
| Lestaurtinib | 14 | 13 | 1 |
| Vemurafenib | 14 | 13 | 1 |
| Tazemetostat | 13 | 13 | 0 |
| Tretinoin | 13 | 7 | 6 |
| Crenolanib | 12 | 11 | 1 |
| Ivosidenib | 12 | 12 | 0 |
| Prednisone | 11 | 11 | 0 |
| Revumenib | 11 | 4 | 7 |
| Chemotherapy | 10 | 8 | 2 |
| Ibrutinib | 10 | 4 | 6 |
| Methotrexate | 10 | 2 | 8 |
| Pexidartinib | 10 | 2 | 8 |
| Asparaginase | 9 | 0 | 9 |
| Larotrectinib | 8 | 8 | 0 |
| Ruxolitinib | 8 | 8 | 0 |
| Palbociclib | 7 | 7 | 0 |
| VTP-50469 | 7 | 0 | 7 |
| Azacitidine | 6 | 6 | 0 |
| Cobimetinib | 6 | 6 | 0 |
| Olaparib | 6 | 6 | 0 |
| Etoposide | 5 | 3 | 2 |
| Trametinib | 5 | 3 | 2 |
| Arabinosylguanine | 4 | 1 | 3 |
| Arsenic Trioxide | 4 | 1 | 3 |
| Asciminib | 4 | 4 | 0 |
| Enasidenib | 4 | 4 | 0 |
| FLT3 Tyrosine Kinase Inhibitor TTT-3002 | 4 | 4 | 0 |
| Gemcitabine | 4 | 0 | 4 |
| Linifanib | 4 | 4 | 0 |
| Nelarabine | 4 | 1 | 3 |
| Olutasidenib | 4 | 4 | 0 |
| R3Mab | 4 | 4 | 0 |
| AG1295 | 3 | 3 | 0 |
| Bafetinib | 3 | 1 | 2 |
| Ceritinib | 3 | 1 | 2 |
| Dabrafenib/Trametinib Regimen | 3 | 3 | 0 |
| Entrectinib | 3 | 3 | 0 |
| Erlotinib | 3 | 3 | 0 |
| FLT3/ABL/Aurora Kinase Inhibitor KW-2449 | 3 | 1 | 2 |
| GSK126 | 3 | 3 | 0 |
| KW2449 | 3 | 3 | 0 |
| Pemigatinib | 3 | 3 | 0 |
| Prednisolone | 3 | 0 | 3 |
| R406 | 3 | 3 | 0 |
| Selumetinib | 3 | 2 | 1 |
| SU5614 | 3 | 0 | 3 |
| AGS324 | 2 | 2 | 0 |
| Anti-CD33 | 2 | 2 | 0 |
| CTX-712 | 2 | 2 | 0 |
| Decitabine | 2 | 2 | 0 |
| FLT3 Inhibitor FF-10101 Succinate | 2 | 2 | 0 |
| Hematopoietic Cell Transplantation | 2 | 2 | 0 |
| JQ-1 | 2 | 2 | 0 |
| Letetresgene Autoleucel | 2 | 2 | 0 |
| Lometrexol | 2 | 2 | 0 |
| Masitinib | 2 | 1 | 1 |
| NSC348884 | 2 | 2 | 0 |
| Omacetaxine Mepesuccinate | 2 | 2 | 0 |
| R-CHOP Regimen | 2 | 1 | 1 |
| RG7112 | 2 | 1 | 1 |
| Salinomycin | 2 | 2 | 0 |
| Sirolimus | 2 | 2 | 0 |
| Tandutinib | 2 | 1 | 1 |
| Tyrphostin AG 1296 | 2 | 2 | 0 |
| Vincristine | 2 | 1 | 1 |
| Ziftomenib | 2 | 2 | 0 |
| 4'-(9-acridinylamino)methanesulfon-m-anisidide | 1 | 0 | 1 |
| 5-Fluoro-2-Deoxycytidine | 1 | 1 | 0 |
| 6-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl)-N-(4-(methylsulfonyl)phenyl)pyridin-2-amine | 1 | 1 | 0 |
| Adavosertib | 1 | 1 | 0 |
| Alemtuzumab | 1 | 1 | 0 |
| ALK Inhibitor TAE684 | 1 | 1 | 0 |
| Anthracycline Antineoplastic Antibiotic | 1 | 0 | 1 |
| Anti-CD123 | 1 | 1 | 0 |
| AS602868 | 1 | 1 | 0 |
| Atezolizumab | 1 | 1 | 0 |
| Avapritinib | 1 | 1 | 0 |
| AZ12908010 | 1 | 0 | 1 |
| Azathioprine | 1 | 0 | 0 |
| BCR-ABL Inhibitor HS-10382 | 1 | 1 | 0 |
| Bone Marrow Transplantation | 1 | 1 | 0 |
| Bortezomib | 1 | 1 | 0 |
| BPTES | 1 | 1 | 0 |
| BRAF Inhibitor | 1 | 1 | 0 |
| Camptothecin | 1 | 1 | 0 |
| Cetuximab | 1 | 1 | 0 |
| CHZ868 | 1 | 1 | 0 |
| Cisplatin | 1 | 1 | 0 |
| Dabrafenib | 1 | 1 | 0 |
| Dexamethasone | 1 | 1 | 0 |
| Dinaciclib | 1 | 0 | 1 |
| Donor Lymphocyte Infusion | 1 | 1 | 0 |
| Dovitinib | 1 | 1 | 0 |
| DVP Regimen | 1 | 0 | 1 |
| Eprenetapopt | 1 | 1 | 0 |
| EPZ004777 | 1 | 1 | 0 |
| EPZ011989 | 1 | 1 | 0 |
| Erdafitinib | 1 | 1 | 0 |
| Fedratinib | 1 | 1 | 0 |
| Fexagratinib | 1 | 0 | 1 |
| Fludarabine | 1 | 1 | 0 |
| Galiximab | 1 | 1 | 0 |
| Gefitinib | 1 | 1 | 0 |
| Gemtuzumab Ozogamicin | 1 | 1 | 0 |
| GSK321 | 1 | 1 | 0 |
| Guadecitabine | 1 | 1 | 0 |
| GW-2580 | 1 | 1 | 0 |
| HDAC Inhibitor OBP-801 | 1 | 1 | 0 |
| HyperCVAD Regimen | 1 | 1 | 0 |
| I-BET151 | 1 | 1 | 0 |
| Idarubicin | 1 | 1 | 0 |
| IMG-2005-5 | 1 | 1 | 0 |
| Ipilimumab | 1 | 1 | 0 |
| IRAK-1/4 Inhibitor | 1 | 1 | 0 |
| Irinotecan | 1 | 1 | 0 |
| JAK Inhibitor I | 1 | 1 | 0 |
| JQ1 | 1 | 1 | 0 |
| JQEZ5 | 1 | 1 | 0 |
| K 252a | 1 | 0 | 1 |
| Lenalidomide | 1 | 0 | 1 |
| Mcl-1 Inhibitor MIK665 | 1 | 1 | 0 |
| Menin Inhibitor | 1 | 1 | 0 |
| MTOR Inhibitor | 1 | 1 | 0 |
| MVT Regimen | 1 | 0 | 1 |
| NCT00137111 | 1 | 1 | 0 |
| Ningetinib | 1 | 1 | 0 |
| Nirogacestat | 1 | 1 | 0 |
| Not Applicable | 1 | 0 | 0 |
| OICR-9429 | 1 | 1 | 0 |
| Pacritinib | 1 | 1 | 0 |
| Panobinostat | 1 | 1 | 0 |
| PD173074 | 1 | 0 | 1 |
| Peginterferon Alfa-2a | 1 | 1 | 0 |
| Peginterferon Alfa-2b | 1 | 1 | 0 |
| Pixantrone | 1 | 0 | 1 |
| Pomalidomide | 1 | 0 | 1 |
| Selinexor | 1 | 0 | 1 |
| Tamibarotene | 1 | 0 | 1 |
| Therapeutic Glucocorticoid | 1 | 0 | 1 |
| Tirbanibulin | 1 | 1 | 0 |
| Tisagenlecleucel | 1 | 0 | 1 |
| Tofacitinib | 1 | 1 | 0 |
| Tunlametinib | 1 | 1 | 0 |
| Tyrosine Kinase Inhibitor | 1 | 1 | 0 |
| Tyrphostin AG 1295 | 1 | 1 | 0 |
| Valproic Acid | 1 | 1 | 0 |
| Vandetanib | 1 | 1 | 0 |
| VTP50469 | 1 | 1 | 0 |
Curated Items are counted regardless of level or direction; see the evidence tab for the detail.